JP2018514510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514510A5 JP2018514510A5 JP2017549388A JP2017549388A JP2018514510A5 JP 2018514510 A5 JP2018514510 A5 JP 2018514510A5 JP 2017549388 A JP2017549388 A JP 2017549388A JP 2017549388 A JP2017549388 A JP 2017549388A JP 2018514510 A5 JP2018514510 A5 JP 2018514510A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- subject
- pharmaceutical composition
- use according
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 206010019860 Hereditary angioedema Diseases 0.000 claims 17
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 3
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 3
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- 102000010631 Kininogens Human genes 0.000 claims 1
- 108010077861 Kininogens Proteins 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021204200A JP7309836B2 (ja) | 2015-03-30 | 2021-12-16 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
| JP2023110592A JP2023130442A (ja) | 2015-03-30 | 2023-07-05 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140289P | 2015-03-30 | 2015-03-30 | |
| US201562140277P | 2015-03-30 | 2015-03-30 | |
| US62/140,289 | 2015-03-30 | ||
| US62/140,277 | 2015-03-30 | ||
| US201562214293P | 2015-09-04 | 2015-09-04 | |
| US62/214,293 | 2015-09-04 | ||
| PCT/US2016/024921 WO2016160926A1 (en) | 2015-03-30 | 2016-03-30 | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204200A Division JP7309836B2 (ja) | 2015-03-30 | 2021-12-16 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514510A JP2018514510A (ja) | 2018-06-07 |
| JP2018514510A5 true JP2018514510A5 (cg-RX-API-DMAC7.html) | 2019-05-09 |
| JP7008920B2 JP7008920B2 (ja) | 2022-01-25 |
Family
ID=57005262
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549388A Active JP7008920B2 (ja) | 2015-03-30 | 2016-03-30 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
| JP2021204200A Active JP7309836B2 (ja) | 2015-03-30 | 2021-12-16 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
| JP2023110592A Pending JP2023130442A (ja) | 2015-03-30 | 2023-07-05 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204200A Active JP7309836B2 (ja) | 2015-03-30 | 2021-12-16 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
| JP2023110592A Pending JP2023130442A (ja) | 2015-03-30 | 2023-07-05 | 血漿カリクレイン阻害剤および遺伝性血管浮腫発作を予防するためのその使用 |
Country Status (14)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3459564T1 (sl) | 2010-01-06 | 2022-06-30 | Takeda Pharmaceutical Company Limited | Proteini, ki vežejo plazemski kalikrein |
| JP2014506257A (ja) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
| CN111704672B (zh) | 2013-03-15 | 2024-06-04 | 武田药品工业株式会社 | 抗血浆激肽释放酶抗体 |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| IL295414B1 (en) | 2014-03-27 | 2025-10-01 | Takeda Pharmaceuticals Co | Compositions and methods for treating macular edema due to diabetes |
| US11286307B2 (en) * | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| BR112019005167A2 (pt) * | 2016-09-16 | 2019-07-02 | Dyax Corp. | método e kit para analisar uma amostra |
| JP7210540B2 (ja) * | 2017-08-04 | 2023-01-23 | 武田薬品工業株式会社 | 血漿カリクレインの阻害剤およびその使用 |
| WO2019166572A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| CA3092538A1 (en) * | 2018-02-28 | 2019-09-06 | Lifesci Pharmaceuticals, Inc. | Treatment of hereditary angioedema |
| MX2021002349A (es) * | 2018-08-30 | 2021-05-31 | Takeda Pharmaceuticals Co | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. |
| CN114166924B (zh) * | 2021-12-03 | 2024-11-22 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| ES2227545T3 (es) | 1994-01-11 | 2005-04-01 | Dyax Corporation | Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina. |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DE60333758D1 (de) | 2002-06-07 | 2010-09-23 | Dyax Corp | Prevention und Verringerung von Ischemia |
| US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| SI3459564T1 (sl) * | 2010-01-06 | 2022-06-30 | Takeda Pharmaceutical Company Limited | Proteini, ki vežejo plazemski kalikrein |
| JP2014506257A (ja) * | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
| WO2012151247A2 (en) * | 2011-05-02 | 2012-11-08 | Millennium Pharmaceuticals, Inc. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| EP3456744B1 (en) * | 2013-01-20 | 2023-03-29 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| CN111704672B (zh) * | 2013-03-15 | 2024-06-04 | 武田药品工业株式会社 | 抗血浆激肽释放酶抗体 |
| KR20140119396A (ko) * | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| AU2014340450B2 (en) * | 2013-10-21 | 2020-05-21 | Takeda Pharmaceutical Company Limited | Assays for determining plasma kallikrein system biomarkers |
| EA038532B1 (ru) * | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
-
2016
- 2016-03-30 EP EP16774069.5A patent/EP3286226A4/en not_active Withdrawn
- 2016-03-30 WO PCT/US2016/024921 patent/WO2016160926A1/en not_active Ceased
- 2016-03-30 KR KR1020177031279A patent/KR102607829B1/ko active Active
- 2016-03-30 US US15/562,671 patent/US20180298110A1/en not_active Abandoned
- 2016-03-30 KR KR1020257012913A patent/KR20250057946A/ko active Pending
- 2016-03-30 HK HK18110329.1A patent/HK1250995A1/zh unknown
- 2016-03-30 JP JP2017549388A patent/JP7008920B2/ja active Active
- 2016-03-30 AU AU2016243160A patent/AU2016243160B2/en active Active
- 2016-03-30 CN CN201680018200.7A patent/CN107614532A/zh active Pending
- 2016-03-30 EA EA201792161A patent/EA201792161A1/ru unknown
- 2016-03-30 BR BR112017020864-4A patent/BR112017020864A2/en not_active Application Discontinuation
- 2016-03-30 IL IL305207A patent/IL305207A/en unknown
- 2016-03-30 IL IL254292A patent/IL254292B1/en unknown
- 2016-03-30 MX MX2017012423A patent/MX2017012423A/es unknown
- 2016-03-30 CA CA2979713A patent/CA2979713A1/en active Pending
- 2016-03-30 EP EP21167802.4A patent/EP3916020A1/en active Pending
- 2016-03-30 KR KR1020237040648A patent/KR102799778B1/ko active Active
-
2017
- 2017-09-15 CO CONC2017/0009404A patent/CO2017009404A2/es unknown
- 2017-09-27 MX MX2023010206A patent/MX2023010206A/es unknown
-
2021
- 2021-10-13 US US17/500,214 patent/US20220169749A1/en active Pending
- 2021-12-16 JP JP2021204200A patent/JP7309836B2/ja active Active
-
2022
- 2022-05-12 AU AU2022203180A patent/AU2022203180B2/en active Active
-
2023
- 2023-07-05 JP JP2023110592A patent/JP2023130442A/ja active Pending
-
2025
- 2025-11-21 AU AU2025271115A patent/AU2025271115A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514510A5 (cg-RX-API-DMAC7.html) | ||
| JP7194022B2 (ja) | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 | |
| Wehler et al. | A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer | |
| WO2019096194A1 (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2017503820A5 (cg-RX-API-DMAC7.html) | ||
| Wong et al. | Vancomycin hypersensitivity: synergism with narcotics and" desensitization" by a rapid continuous intravenous protocol | |
| WO2018068691A1 (zh) | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 | |
| JP2022033868A5 (cg-RX-API-DMAC7.html) | ||
| JP2019501886A5 (cg-RX-API-DMAC7.html) | ||
| JP2019514974A5 (cg-RX-API-DMAC7.html) | ||
| JP2020521797A5 (cg-RX-API-DMAC7.html) | ||
| JP2020535149A5 (cg-RX-API-DMAC7.html) | ||
| Takeuchi et al. | OP0040 adding tocilizumab or switching to tocilizumab monotherapy in RA patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (Surprise Study) | |
| Bernstein et al. | Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks | |
| Fenier et al. | Enalapril improved renal function and proteinuria in chronic glomerulopathies | |
| Pressiani et al. | Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer | |
| Miller et al. | Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease—the DIVINE study | |
| US20230038138A1 (en) | Combination therapy for treating cancer | |
| Patel et al. | Amlodipine overdose | |
| JP2024174997A (ja) | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 | |
| JPWO2020186132A5 (cg-RX-API-DMAC7.html) | ||
| ZAREEIFAR et al. | Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia | |
| Yoshida et al. | Dexamethasone as a means not only for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein but also for controlling oxaliplatin-induced hypersensitivity reactions. | |
| RU2019108441A (ru) | Режим дозирования | |
| WO2019129168A1 (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 |